{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-125092","form_type":"8-K","ticker":"WVE","cik":"0001631574","company_name":"Wave Life Sciences Ltd.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.691939+00:00","generated_at":"2026-05-15T08:50:25.962738+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Wave Life Sciences Announces Positive Interim Phase 1 Data for WVE-007 in Obesity Trial","bullets":["Single 240 mg dose of WVE-007 reduced visceral fat by 14% (placebo-adjusted, p<0.05) at six months.","WVE-007 showed preservation of lean mass (+2%) and waist circumference reduction (-3%) at six months.","Phase 2a portion of INLIGHT in higher BMI (35-50 kg/m2) to initiate in 2Q 2026.","WVE-007 continues to be generally safe and well tolerated with no severe TEAEs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-125092","json":"https://secwatch.observer/filing/0001193125-26-125092.json","markdown":"https://secwatch.observer/filing/0001193125-26-125092.md","text":"https://secwatch.observer/filing/0001193125-26-125092.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526125092/0001193125-26-125092-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526125092/d17239d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud","generated_at":"2026-05-15T08:50:25.962738+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}